Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT04467281
A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma
Overview
The purpose of this study is to see if using the radioactive tracer 89Zr-DFO-daratumumab with PET/CT scans is a practical and effective way to view and monitor multiple myeloma in participants before and during their treatment with daratumumab. We also want to see if 89Zr-DFO-daratumumab PET/CT scans can predict a participant's response to therapy, and if they can better locate any leftover disease following treatment compared to the standard imaging methods.
Sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Contacts
Marius Mayerhoefer, MD, PhD (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT04467281Eligibility
Inclusion
- At least one tumor lesion on CT, MRI, or FDG PET/CT within 90 days of protocol enrollment
- ECOG performance status 0 to 2
- Histologically/immunohistochemistry-confirmed CD38-positive multiple myeloma
Exclusion
- Life expectancy \< 12 months
- Patients who cannot undergo PET/CT scanning because of weight limits. PET/CT scanners may not be able to function with patients over 450 pounds.
- History of anaphylactic reaction to humanized or human antibodies.
- Pregnancy or lactation
- Previous treatment with daratumumab. Previous treatment with other myeloma therapies will be allowed.
Share your feedback
Help us improve your experience